Breathing new life into rare respiratory disease treatment
Savara Inc. (Nasdaq: SVRA) is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its lead product candidate, molgramostim inhalation solution (MOLBREEVI), is an inhaled recombinant GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease causing progressive respiratory failure.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account